KRAS and non-small cell lung carcinoma: Given the clinical data demonstrating patients with KRAS-driven NSCLC lacking functional STK11 respond poorly to anti-PD-1 mono-therapy (10), our analyses of un- and under-characterized STK11 variants provides critical pre-clinical evidence that can be used to help guide oncologic care for the ~15 000 patients diagnosed annually with KRAS-driven, STK11-mutated NSCLC.